Toray develops KSB-200, next‑generation κOR analgesic candidate
- KSB-200 is a novel κ-opioid receptor (κOR) agonist designed with signaling bias to favor G protein pathways over β-arrestin recruitment.
- Oral KSB-200 demonstrated analgesic activity in a mouse postoperative pain model and suggested better separation of analgesia versus sedation than TRK-820 (nalfurafine).
- Toray links KSB-200 design to experience from TRK-820 and aims to reduce central nervous system side effects such as sedation and dysphoria.
- Toray will present results at the International Narcotics Research Conference 2026 (July 13–16, Denver) and seek partners under its early partnership strategy.
Candidate and rationale
Toray developed KSB-200 as a candidate compound for postoperative pain and other indications. The compound exhibits agonist activity at the kappa opioid receptor (κOR) and was designed to exploit signaling bias at κOR to retain analgesic effects while aiming to reduce central nervous system side effects.
Mechanism and background
KSB-200 was designed to preferentially engage G protein signaling while minimizing β-arrestin recruitment, an approach proposed to preserve analgesia and reduce adverse central effects such as sedation and dysphoria. The program leveraged Toray's experience from research on TRK-820 (nalfurafine hydrochloride).
Preclinical results
In an exploratory mouse model of postoperative pain, oral KSB-200 demonstrated analgesic activity. Results suggested an improved separation between analgesic and sedative effects when compared with TRK-820, a κOR agonist previously studied by the company.
Next steps
Toray will present its findings at the International Narcotics Research Conference 2026 (July 13–16, Denver) and intends to seek partners to advance the KSB-200 program under its early partnership strategy.
Source: Toray
